PCDHB16

Across TCGA pan-cancer cohorts, PCDHB16 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of PCDHB16’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where PCDHB16 RNA is repressed in tumor relative to normal tissue. In most cancer types PCDHB16 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

THCA, KIRC, and KICH are the cancer types where PCDHB16 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PCDHB16 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−1.228	<.001	11	view →
KIRC	All	III,IV	+0.836	<.001	11	view →
KICH	Male	All	−1.495	<.001	9	view →
HNSC	All	All	+0.710	<.001	8	view →
LIHC	All	All	+0.595	<.001	5	view →
STAD	All	IV	+1.876	.005	4	view →
BRCA	All	All	−0.508	<.001	4	view →
CHOL	All	All	+2.062	<.001	2	view →
UCEC	All	All	−1.137	<.001	2	view →
PRAD	All	All	+0.848	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

PCDHB16–THCA

Open the THCA breakdown →